### Understanding the Immune System Using Optimization and Control

Shlomo Ta'asan Carnegie Mellon University shlomo@cmu.edu

Advanced Methods and Perspectives in nonlinear Optimization and Control. ENSIACET, Toulouse, February 3-5, 2010

#### Part I: Control & Optimization in Critical Care Medicine (w/ Pinsky & Hravnak)

• Small dimensional system - complex dynamics

### Part II: Understanding The Immune System in Infectious Diseases (CMPI)

• Huge dimensional system - simple dynamics

## Shock

A physiological state with significant, systemic reduction in tissue perfusion  $\rightarrow$  tissue injury.

#### Four Profiles

Hypovolemic: Decreased preload->small ventricular end-diastolic volumes -> inadequate cardiac generation of pressure and flow

Septic: release of inflammatory mediators

**Cardiogenic:** Intrinsic abnormality of heart -> inability to deliver blood into the vasculature with adequate power

Neurogenic :Loss of autonomic innervation of the cardiovascular system

# Hemodynamic Profiles

	<u>PCWP</u>	<u>CVP</u>	<u>CO/CI</u>	<u>SVR/I</u>
Hypovolemic	Low	Low	Low	High
Cardiogenic	High	High	Low	High
Inflammatory	Low / N	Low/N	High	Low
Neurogenic	Low	Low	Low	Low

**PCWP**: Pulmonary capillary wedge pressure -indirect estimate of left atrial pressure

CVP: Central Venus pressure- a good approximation of right atrial pressure CO/CI: Cardiac Output, Cardiac Index

SVR/I: Systemic Vascular Resistance, Systemic Vascular Resistance Index

#### The four profiles represent different regions in phase space with possibly attractors of different shapes

# **Medical Issues**

- Assessment of severity
- Stratifying the risk for complications
- Gauging the adequacy of therapy
- Estimating improved predictions if additional measurements were supplied
- Need to develop metrics to assess these challenges

# **Chaotic Dynamics**



Mild changes in the attractor over time. Data: Hravnak & Pinsky

## Chaotic Dynamics cont.



Significant changes in the attractor over time. Data: Hravnak & Pinsky

## Mathematical Modeling

### $\textbf{ODE} \quad dX/dt = V(X, \alpha) \quad X(t) \in I\!\!R^n$

Basic model : X(t) - physiological measurements, a - model parameters

Attractor is rough  $\rightarrow$  Add noise to smooth it. Noise may also be biologically relevant

SDE 
$$dX_t = V(X_t, \alpha)dt + \sqrt{2\sigma}dW_t$$

•The attractor is stable under perturbation

Trajectories are sensitive to perturbation

### The Attractor and its Measure

The biologically significant quantity is the measure satisfying the equation

$$div(V(x,\alpha)\rho) - \sigma \triangle \rho = 0$$



represent the fraction of time the trajectory spend in a small volume around x



## Modeling a Patient -System Identification

- Find a model for the chaotic dynamics, i.e, V(x,a), using data  $\rho_d$
- Define a distance  $E(\alpha) = d^2(\rho(\alpha), \rho_d)$
- SysID problem

 $Min_{\alpha} E(\alpha) \quad \text{subject to} \\ div(V(x,\alpha)\rho(x,\alpha)) - \sigma \triangle \rho(x,\alpha) = 0$ 

# The Choice of Distance

• Example

$$E(\alpha) = d^{2}(\rho(\alpha), \rho^{*}) = \|\rho(\alpha) - \rho^{*}\|_{2}^{2}$$

Not a good optimization problem: Functional is flat when the support of the two measures are far apart.

Dist(red, black) ~ Dist(red, blue)

Functional has flat regions!!



## Choice of Distance cont.

• Example II:

 $E(\alpha) = d_w^2(\rho, \bar{\rho})$  2-Wasserstein Distance

- A natural distance between measures.
- Functional is sensitive to changes in the measures even when their supports are far apart.
   Dist(red, black) ~ 3 Dist(red, blue)



### 2-Wasserstein Distance absolutely continuous case

$$d_W^2(\rho,\bar{\rho}) = \min_{\phi_{\#}\rho=\bar{\rho}} \int |\phi(x) - x|^2 \rho(x) dx$$

Or

$$\begin{aligned} d_W^2(\rho,\bar{\rho}) &= \min_{U,W} \int U(x)\rho(x) + \int W(y)\bar{\rho}(y)dy + const.\\ &U(x) + W(y) \leq x \cdot y \end{aligned}$$

Optimality conditions

$$\begin{aligned} U(x) + W(y) &= x \cdot y \quad \text{for} \quad \mu(x, y) > 0\\ \int \mu(x, y) dy &= \rho(x) \quad \int \mu(x, y) dx = \bar{\rho}(y) \quad \mu(x, y) \ge 0 \end{aligned}$$

# **Calculating Gradients**

 $\label{eq:costfunction} {\it E}(\alpha) = d^2_{_W}(\rho,\rho^*)$ 

**Optimization Problem** 

 $Min_{\alpha} E(\alpha) \quad \text{subject to} \\ div(V(x,\alpha)\rho(x,\alpha)) - \sigma \triangle \rho(x,\alpha) = 0 \\ \text{Perturbations:} \end{cases}$ 

$$\begin{array}{l} \alpha \to \alpha + \epsilon \tilde{\alpha} \\ V \to V + \epsilon V_{\alpha} \tilde{\alpha} \\ \rho \to \rho + \epsilon \tilde{\rho} \end{array} \qquad div(\tilde{V}\rho) + div(V\tilde{\rho}) - \sigma \triangle \tilde{\rho} = 0 \end{array}$$

### Gradients Cont.

#### Lagrangian

$$\mathcal{L}(\rho,\lambda,\alpha) = d_W^2(\rho,\rho^*) + \int \lambda (div(V\rho) - \sigma \triangle \rho) dx$$
$$\frac{d}{d\epsilon} d_W^2(\rho + \epsilon \tilde{\rho},\rho^*)|_{\epsilon=0} = \int U(x)\tilde{\rho}(x) dx$$

$$-div(V\lambda) - \sigma \bigtriangleup \lambda = U$$
 Adjoint equation

$$\nabla_{\alpha} E(\alpha) = -\int \rho V_{\alpha} \nabla \lambda dx$$

The Gradient

# **Implementation Details**

• Approximating  $V(x,\alpha)$ 

$$V(x,\alpha) = \alpha_0 + \alpha_1 x + \alpha_2 x x^T$$

#### **Multigrid Solver**

- Variables:  $\rho^h, \lambda^h, U^h, W^h, \alpha$
- FAS transfers between levels.
- Optimizing for  $\alpha\,$  on coarsest levels, pointwise relations for  $\rho^h, \lambda^h, U^h, W^h$

Primal-Dual Formulation  

$$\min_{\alpha,U^{h},W^{h}} \int U^{h}(x)\rho^{h}(x)dx + \int W^{h}(y)\bar{\rho}^{h}(y)dy \quad \text{subject to}$$

$$div_{h}(V(\alpha)\rho^{h}) - \sigma \Delta_{h}\rho^{h} = 0 \quad \int \rho^{h}dx = \int \bar{\rho}^{h}dx$$

$$U^{h}(x) + W^{h}(y) \leq x \cdot y$$

#### Optimality conditions

$$div_{h}(V(\alpha)\rho^{h}) - \sigma \triangle_{h}\rho^{h} = 0 \qquad \int \rho^{h} dx = \int \bar{\rho}^{h} dx$$
$$-div_{h}(V\lambda^{h}) - \sigma \triangle_{h}\lambda^{h} = U \qquad \int \rho^{h}V_{\alpha}\nabla_{h}\lambda^{h} dx = 0$$
$$U^{h}(x) + W^{h}(y) = x \cdot y \quad \text{for} \quad \mu^{h}(x,y) > 0$$
$$\int \mu^{h}(x,y) dy = \rho^{h}(x) \qquad \int \mu^{h}(x,y) dx = \bar{\rho}^{h}(y) \quad \mu^{h}(x,y) \ge 0$$

## Designing Treatment Using Control Theory

Medicine tells us that some  $\rho^*$  are 'good'. They characterize healthy people. Or that some regions in the phase space are 'bad' (Four profiles)

Biological parameters are implicit in  $V(x, \alpha)$ A control problem:  $E(\alpha) = d_W^2(\rho(\alpha), \rho^*)$ 

**Treatment Design** 

 $Min_{\alpha} E(\alpha) \quad \text{subject to} \\ div(V(x,\alpha)\rho(x,\alpha)) - \sigma \triangle \rho(x,\alpha) = 0$ 

# **Additional Functions**

The probability that we are in a 'bad' region A  $\int_A \rho(x) dx$ 

Recall the four profiles (Hypovolemic, Cardiogenic Inflammatory, Neurogenic) - 'bad' regions of the phase space

 $\text{Enforcing constraints } \int_A \rho(x) dx \leq \eta$ 

Or modifying cost function

$$E(\alpha) = d_W^2(\rho(\alpha), \bar{\rho}) + \beta \int_A \rho(x) dx$$

### Relating Physiological Measurements and Model Coefficients

#### Treatment affects dynamics parameters a.

 Hypovolemic : ABCs, IVF (crystalloid), Transfusion Stem ongoing Blood Loss
 Septic: ABCs, IVF, Blood cx, ABX, Drainage, pressors
 Cardiogenic : <u>CHF</u>- diuretics & vasodilators +/- pressors. <u>LV failure</u> - pressors, intra aortic balloon pump & ventricular assist device.
 Neurogenic: IVF, vasoactive medications if refractory

#### **Need:** α sensitivities with respect to all treatments



## Medical Challenges and Mathematical Formulations

• Assessment of severity

W-distance from 'healthy' attractors

- Stratifying the risk for complications
   Probability to be in certain regions of phase space
- Gauging the adequacy of therapy Change of cost function with treatment
- Estimating Improved Predictions if additional measurements were supplied

Comparing higher dimensional models (more measurements) with lower dimensional ones

### Understanding The Immune System in Infectious Diseases

NIH Biodefense Center for Modeling Pulmonary Immunity University of Pittsburgh **Carnegie Mellon** University of Michigan Penny Morel, PI Shlomo Ta'asan, co-PI Denise Kirschner Experiments Jerry Nau Emrah Diril Math Modeling Simeone Marino Ted Ross Ziv Bar-Joseph **Benoit Morel** Russ Salter Jason Ernst Joanne Flynn Takis Benos Statistical Analysis Shaun Mahony Panos Chrysanthis Bioinformatics Alex Labrinidis

# The Immune System

• The Players:

Organs (handful), cells (~2 dozen), molecules (~2000), genes

The Pathogens

Viruses, Bacteria, Parasites, Fungi

- The State of the System: High dimension
- Its Purpose

Eradicate pathogens, tissue repair.







www.cancer.gov/cancertopics/understandingcancer/immunesystem



www.cancer.gov/cancertopics/understandingcancer/immunesystem

## The Interactions

- Immune System Cells Can
  - Receive to a set of messages (R)
  - Transmit a set of messages (T)
  - May change the set R & T upon receiving  $r \in R$
  - Secrete effector molecules (antibodies, toxins,..)
  - Damage tissue (secretion of toxins)
  - Repair tissue (secretion of growth factors)
  - Eradicate pathogens

#### An orchestra without a conductor!!

### **Modeling Approaches**

#### **Traditional Modeling**

- Biological knowledge & hypotheses are translated into mathematics.
- The role of math is to refine our understanding (parameter ranges, ...).

#### System Identification Black-Box Modeling

- Experimental data with little or no explanation is given.
- A mathematical formulation is done to 'discover' the



### System Identification Data Driven -Black Box Modeling

- Define a class of models
  - Linear, nonlinear, ...
- Find the model in this class that best fit the data.
- Important Features:

No biological knowledge is used! The meaning of data is insignificant!

SysID approach is now possible due to recent revolution in experimental techniques  $\rightarrow$  abundant data at multiple scales



Concentration

### The Driving Questions:

#### How complex is the response?

- how many variables are needed?
- how complex is the dynamics?

#### How to control it?

- which interventions (variables) are most effective?
- how to apply these interventions?
- vaccination:

what parameters does vaccination change?

Very different from traditional approach: assuming no prior biological knowledge

### Understanding Response

- Dynamics on high dimensional manifold
- Building Approximations
  - Approximate space affine variety
  - Approximate dynamics linear, nonlinear
- Inverse problems
  - Data  $\rightarrow$  Models  $\rightarrow$  Intervention

### System Identification Approach

Assumptions

• The immune system can be approximated as a large set of nonlinear equations

$$\frac{dX}{dt} = f(X) \qquad X = (x_1, \cdots, x_N)$$

• The immune system is in steady state in the absence of challenges

$$f(X) = 0 \qquad X = (x_1, \cdots, x_N)$$

• Important information about the system can be obtained from studying small perturbations.

Small perturbations of the immune system satisfy linear systems of equation

$$\left| \frac{dY}{dt} = AY \quad Y = (y_1, \cdots, y_N) \quad y$$
-equation

#### **Incomplete Information**

Measurements of the system are only partial !!

$$V = (v_1, \cdots, v_K) \qquad K \ll N$$

V(t) need not satisfy a similar equation to Y(t). In general, the model for V(t) is

$$\frac{d^{n}V}{dt^{n}} = A_{1}\frac{d^{n-1}Y}{dt^{n-1}}V + A_{2}\frac{d^{n-1}V}{dt^{n-1}}V + \dots + A_{n}V$$

The Modeling Problem: Find the Coefficients A1, ... An

The Approach: Find the coefficients that fit the data the best.

#### **Continuous Time Models**



Higher order models are also possible.

Objective: Construct a model from measurements of X at different times.

### **Continuous Time Models** -Intervention Design



Objective: Design a drug mixture B and its administration u(t), that is 'best' for ...

#### **Discrete Time Models**

Equal Time Intervals  $\rightarrow$  Can use discrete models

 $X_n$  The state of the animal at time n = 0,1,2,...



Higher order models are also possible.

Objective: Construct a model from measurements of X at different times.

### Discrete Time Models : Intervention Design

$$u_n$$
 Drug amount at time n = ,1,2,...

*B* The drugs mixture



$$X_n = AX_{n-1} + Bu_{n-1}$$

 $X_{n} = A_{1}X_{n-1} + A_{2}X_{n-2} + Bu_{n-1}$ 

#### First Order Model

Second Order Model

Objective: Design a drug mixture B, and its administration  $u_n$  for a 'best' outcome ...

### **Formulation Summary**



Intervention Design

Model 
$$x_n = Ax_{n-1} + Bu_{n-1}$$

Timing and amount Given B , (drug mixture) find 'best'  $u_n$  using control theory

**Drug design:** Use optimization to find best B:

$$\min_{B} J(x(B, u), u(B))$$

#### Nonlinear Data Driven Models

(1)

Quadratic nonlinearities  $dX/dt = L X + N X X^{T}$ 

Or discrete time models

$$X_{n+1} = L X_n + N X_n X_n^{T}$$
 (2)

Min<sub>L,N</sub>  $\sum || X_n - X_n^* ||^2$  subject to (2)

### Modeling Influenza A in Adult Mice



Mo IL-10 (36) 0 1200 Mo TNF-a (6) 0 0 Mo IL-1a (37) Mo IL-12(p40) (57) 0 1000 Mo IL-12(p70) (50) 0 0 Mo MIP-1b (59) Weight Loss 800 0 600 400 00 200 x 10<sup>5</sup> Influenza-A Adult - 1st order model (Set 3) Virus 0 0 2.5 2 1.5 1 0.5 00 5 10 15 20 25 Processed Data(o) vs Model(-) Error = 7.55%

Influenza-A Adult - 1st order model (Set 2)

#### Modeling with Limited Data - case I







### Modeling with Limited Data - case II





#### **Intervention** Design

Model 
$$x_n = Ax_{n-1} + Bu_{n-1}$$

Timing & Given B , (drug mixture) find 'best'  $u_n$  using Amount control theory

Drug design: Use optimization to find best B:

 $\min_{B \in C} J(x(B, u), u(B))$ 

#### Intervention Design Anne Yust Drug Mixture

Attempt to control mouse weight loss (illness indicator) + virus load

**Elderly Mice** 



#### Modeling Francisella Tularensis in Mice

#### • Schu S4 strain vs. LVS



#### **FT Intervention Design**

- Using Control theory. IFN  $\gamma$  intervention at day 1 of infection













### Thank You